Fort Myers-based cancer testing and research lab NeoGenomics expects to report double-digit revenue growth for 2025. However, ...
NeoGenomics (NASDAQ:NEO) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement. Analysts estimate that NeoGenomics will ...
Hosted on MSN
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance
NeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a shocking sell-off after Chief Executive Chris Smith announced his retirement on Monday.
On Thursday, Benchmark analyst maintained a Hold rating on shares of Neogenomics (NASDAQ: NEO). The analysis comes ahead of the company's investor conference presentation scheduled for the same day.
FORT MYERS, Fla. and FREMONT, Calif., April 29, 2025 /PRNewswire/ -- NeoGenomics, Inc. (NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, and Ultima Genomics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback